RBAK inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of RBAK, a protein involved in transcriptional regulation and cellular signaling. RBAK, also known as Repressor of the RB Transcriptional Corepressor, is associated with the regulation of gene expression through its interaction with the retinoblastoma (RB) protein. RBAK functions as a transcriptional repressor by binding to the RB protein and other transcriptional machinery, thereby influencing the expression of genes that control cell cycle progression, differentiation, and growth. It plays a crucial role in maintaining cellular homeostasis by modulating the transcription of genes that are involved in critical cellular processes. Inhibitors of RBAK disrupt its ability to interact with the RB protein and other components of the transcriptional complex, thereby altering the normal transcriptional repression activity.
Inhibition of RBAK can lead to changes in the expression of genes that are typically repressed by this protein, particularly those involved in the regulation of cell proliferation and differentiation. By blocking RBAK's function, these inhibitors interfere with the molecular pathways that control gene silencing, allowing for the potential activation of previously repressed genes. Researchers utilize RBAK inhibitors to study the specific role of RBAK in transcriptional regulation, providing insights into how it interacts with the RB protein and other regulatory factors to influence gene expression. These inhibitors are valuable tools for investigating the broader mechanisms of transcriptional control, helping scientists understand the complex interactions between transcriptional repressors and their target genes. Additionally, RBAK inhibitors shed light on the importance of transcriptional repressors in regulating the balance between cell growth and quiescence, offering deeper insights into the molecular pathways that maintain cellular function and prevent uncontrolled cell proliferation. Through these studies, researchers can further explore the role of RBAK in maintaining the regulation of critical cellular processes at the transcriptional level.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could downregulate RBAK expression by inducing global DNA demethylation, which may reactivate genes that suppress RBAK transcription or disrupt methylation-dependent enhancer elements essential for RBAK gene activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A might decrease RBAK transcription by promoting acetylation of histones, thereby changing the chromatin structure around the RBAK promoter to a state less conducive to the binding of transcription factors essential for RBAK expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid has the potential to reduce RBAK expression levels by inhibiting histone deacetylases, which may result in an increase in histone acetylation near the RBAK gene, leading to the attenuation of transcriptional activity. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
RG 108 could inhibit the expression of RBAK by blocking DNA methyltransferase enzymes, possibly preventing the methylation of the RBAK promoter region and thereby reducing its transcriptional initiation. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine may target hypermethylated promoters of tumor suppressor genes, reactivating these genes, which could then reduce the expression of downstream targets like RBAK through transcriptional repression mechanisms. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A might specifically bind to G-C rich regions of DNA, potentially displacing transcription factors from the RBAK gene promoter and leading to a decrease in RBAK gene transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid could downregulate RBAK by binding to retinoic acid receptors, which may alter the transcriptional control of the RBAK gene, leading to decreased mRNA synthesis. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea might reduce RBAK expression by disrupting the deoxyribonucleotide pool balance, creating a bottleneck in DNA replication and repair that could lead to a reduction in RBAK gene transcription as cells slow their division. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, as a tyrosine kinase inhibitor, might decrease RBAK expression by disrupting specific phosphorylation-dependent signaling pathways that are necessary for the initiation of RBAK gene transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin could inhibit RBAK expression by binding to mTOR and thereby reducing protein synthesis rates, including the rate of synthesis of transcription factors that activate RBAK gene transcription. | ||||||